The focus of research in the Fruman Lab is signal transduction in lymphocytes and leukemia cells.

Our long-term goal is to define signaling components whose function is specific to particular immune cell types or responses.

Our rationale is that such components could prove useful as therapeutic targets for immunological diseases and cancer.

Work in our laboratory is divided into three general areas:

(1) Function of PI3K/mTOR/eIF4F pathway components in immune cells;

(2) Targeting the PI3K/mTOR/eIF4F pathway in leukemia and autoimmune diseases

(3) Repurposing statins to enhance killing of blood cancer cells by BH3 mimetics such as venetoclax.